	US 12,214,013 B2
	Methods of treatment of arthritis and/or psoriasis with pharmaceutical formulations of etanercept
Monica Goss, Newbury Park, CA (US); and Nicole Ball, Thousand Oaks, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Filed by AMGEN INC., Thousand Oaks, CA (US)
Filed on Sep. 16, 2022, as Appl. No. 17/933,055.
Application 17/933,055 is a division of application No. 16/144,120, filed on Sep. 27, 2018, granted, now 11,491,223.
Application 16/144,120 is a division of application No. 15/958,261, filed on Apr. 20, 2018, granted, now 10,307,483, issued on Jun. 4, 2019.
Application 15/958,261 is a continuation of application No. 15/788,762, filed on Oct. 19, 2017, abandoned.
Claims priority of provisional application 62/411,458, filed on Oct. 21, 2016.
Prior Publication US 2023/0080571 A1, Mar. 16, 2023
Int. Cl. A61P 19/02 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); A61K 47/02 (2006.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01); A61K 47/68 (2017.01); A61P 17/06 (2006.01); A61P 29/00 (2006.01); C07K 14/715 (2006.01); C07K 19/00 (2006.01)

CPC A61K 38/1793 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 39/39591 (2013.01); A61K 47/02 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01); A61K 47/68 (2017.08); A61P 17/06 (2018.01); A61P 19/02 (2018.01); A61P 29/00 (2018.01); C07K 14/7151 (2013.01); C07K 19/00 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01)]

48 Claims

1. A method of treating a patient having rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or psoriasis, comprising administering to said patient a pharmaceutical composition comprising between 75 mM and 150 mM NaCl, between 5 mM and 100 mM arginine, between 0.5% and 2% (w/v) sucrose, and between 40 mg/mL and 100 mg/mL etanercept, wherein the pharmaceutical composition comprises less than 2.0 mM total additional buffering agent, and the pH of the pharmaceutical composition is between 6.1 and 6.5.